Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

[Cost-effectiveness of exenatide versus insulin glargine in Spanish patients with obesity and type 2 diabetes mellitus].

Goodall G, Costi M, Timlin L, Reviriego J, Sacristán JA, Smith-Palmer J, Dilla T.

Endocrinol Nutr. 2011 Aug-Sep;58(7):331-40. doi: 10.1016/j.endonu.2011.04.005. Spanish.

PMID:
21719364
2.

Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland.

Brändle M, Erny-Albrecht KM, Goodall G, Spinas GA, Streit P, Valentine WJ.

Int J Clin Pharmacol Ther. 2009 Aug;47(8):501-15.

PMID:
19640359
3.

The cost-effectiveness of exenatide once weekly compared with exenatide twice daily and insulin glargine for the treatment of patients with type two diabetes and body mass index ≥30 kg/m(2) in Spain.

Fonseca T, Clegg J, Caputo G, Norrbacka K, Dilla T, Alvarez M.

J Med Econ. 2013 Jul;16(7):926-38. doi: 10.3111/13696998.2013.803110.

PMID:
23659201
4.

Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US.

Samyshkin Y, Guillermin AL, Best JH, Brunell SC, Lloyd A.

J Med Econ. 2012;15 Suppl 2:6-13. doi: 10.3111/13696998.2012.708691.

PMID:
22793669
5.

Clinical and economic outcomes in patients with type 2 diabetes initiating insulin glargine disposable pen versus exenatide BID.

Baser O, Wei W, Baser E, Xie L.

J Med Econ. 2011;14(6):673-80. doi: 10.3111/13696998.2011.605818.

PMID:
21892858
6.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
7.
8.
9.

Cost effectiveness of insulin glargine plus oral antidiabetes drugs compared with premixed insulin alone in patients with type 2 diabetes mellitus in Canada.

Tunis SL, Sauriol L, Minshall ME.

Appl Health Econ Health Policy. 2010;8(4):267-80. doi: 10.2165/11535380-000000000-00000.

PMID:
20578781
10.

Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents.

Valentine WJ, Palmer AJ, Lammert M, Langer J, Brändle M.

Clin Ther. 2011 Nov;33(11):1698-712. doi: 10.1016/j.clinthera.2011.09.022.

PMID:
22018679
11.

A comparison of costs among patients with type 2 diabetes mellitus who initiated therapy with exenatide or insulin glargine.

Misurski D, Lage MJ, Fabunmi R, Boye KS.

Appl Health Econ Health Policy. 2009;7(4):245-54. doi: 10.2165/11318730-000000000-00000.

PMID:
19905038
12.

Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes.

Ray JA, Boye KS, Yurgin N, Valentine WJ, Roze S, McKendrick J, Tucker DM, Foos V, Palmer AJ.

Curr Med Res Opin. 2007 Mar;23(3):609-22.

PMID:
17355742
13.

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.

Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG; GWAA Study Group..

Ann Intern Med. 2005 Oct 18;143(8):559-69.

PMID:
16230722
15.

Evaluation of exenatide vs. insulin glargine in type 2 diabetes: cost-effectiveness analysis in the German setting.

Mittendorf T, Smith-Palmer J, Timlin L, Happich M, Goodall G.

Diabetes Obes Metab. 2009 Nov;11(11):1068-79. doi: 10.1111/j.1463-1326.2009.01099.x.

PMID:
19732121
17.
18.

Comparative efficacy of exenatide versus insulin glargine on glycemic control in type 2 diabetes mellitus patients inadequately treated with metformin monotherapy.

Karagianni P, Polyzos SA, Kartali N, Zografou I, Sambanis C.

Adv Med Sci. 2013;58(1):38-43. doi: 10.2478/v10039-012-0078-7.

PMID:
23640946
19.

Glycemic control with insulin glargine plus insulin glulisine versus premixed insulin analogues in real-world practices: a cost-effectiveness study with a randomized pragmatic trial design.

Levin PA, Zhang Q, Mersey JH, Lee FY, Bromberger LA, Bhushan M, Bhushan R.

Clin Ther. 2011 Jul;33(7):841-50. doi: 10.1016/j.clinthera.2011.05.091.

PMID:
21719107
20.

Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in Spain.

Shearer AT, Bagust A, Ampudia-Blasco FJ, Martínez-Lage Alvarez B, Pérez Escolano I, París G.

Pharmacoeconomics. 2006;24 Suppl 1:49-59. Review.

PMID:
16800162

Supplemental Content

Support Center